The EPS decline has disappointed the market, leaving investo...

The EPS decline has disappointed the market, leaving investors hesitant to buy. Shareholders face a total loss of 3% per year over five years due to the company's poor performance.

Jafron BiomedicalLtd's (SZSE:300529) Earnings Trajectory Could Turn Positive as the Stock Increases 7.1% This Past Week

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

1067 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4191Followers

0Following

9229Visitors